The Scottish Medicines Consortium (SMC) has approved Kite’s CAR T-cell therapy, Yescarta (axi-cel), for treating adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell ...

Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...

Johnson & Johnson has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved BALVERSA (erdafitinib) for treating adults with unresectable or metastatic ...

The World Health Organization’s (WHO) newly published report has placed tuberculosis (TB) as the leading infectious disease killer in 2023, surpassing COVID-19. Newly identified TB cases climbed to ...

The new Dementia Trials Accelerator is set to receive £20m of government funding The Dementia Trials Accelerator, led by the UK Dementia Research Institute and Health Data Research UK and funded by ...

When I first entered the clinical research industry more than 20 years ago, trials were focused mainly on recruitment goals and data collection, with less attention to the challenges faced by research ...

AstraZeneca’s Andrea Mugan shares her unique perspectives on patients, experience, change and challenges ...

Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Voydeya (danicopan). This first-in-class, oral ...

Valneva Scotland has partnered with Team Jak, a West Lothian-headquartered charity focused on supporting children and young people with cancer. The Livingston-based vaccine producer will provide ...

There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an oral formulation of its lead peptide “significantly augmented” the anti-tumour ...

Dundee-based Ubiquigent Limited and San Francisco’s Alleo Labs Corp have entered a strategic partnership to advance deubiquitinase (DUB)-focused drug discovery using AI. The collaboration aims to ...

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma Vivan Therapeutics has signed a new five-year lease at White City Place, a biotech hub in London home to ...